Clinical Trials Logo

Relapsed clinical trials

View clinical trials related to Relapsed.

Filter by:
  • None
  • Page 1

NCT ID: NCT06265545 Not yet recruiting - AML Clinical Trials

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.

NCT ID: NCT05673057 Recruiting - Leukemia Clinical Trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Start date: December 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

NCT ID: NCT03881774 Recruiting - B Cell Lymphoma Clinical Trials

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells

NCT ID: NCT03881761 Recruiting - Refractory Clinical Trials

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Start date: February 1, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma

NCT ID: NCT03179930 Active, not recruiting - Lymphoma Clinical Trials

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Start date: June 7, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.

NCT ID: NCT03085173 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Start date: March 15, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this phase I study is to test the safety of different dose levels of specially prepared cells collected from the patient called "modified T cells". The investigators want to find a safe dose of modified T cells for patients with this type of cancer that has progressed after standard therapy. The investigators also want to find out what effects these modified T cells have on the patient and the cancer. For patients who were treated, had progression of disease and were removed from study, duplicate enrollment is permitted if it is determined the patients could receive a benefit. If the patients meet all eligibility criteria, they can be enrolled onto study a second time as a new accrual, and receive treatment in a higher dose level cohort.

NCT ID: NCT02677064 Recruiting - Acute Leukemia Clinical Trials

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Start date: February 2016
Phase:
Study type: Observational

The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.